Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its subsidiary, Sapu Nano, will present new data on everolimus toxicology at the Society of Toxicology (SOT) 2026 Annual Meeting and ToxExpo in San Diego. The presentation, scheduled for the upcoming meeting, will highlight findings on tissue concentration–driven effects and organ-specific outcomes that extend beyond traditional plasma pharmacokinetics. This research underscores the importance of understanding tissue-level drug distribution in determining toxicity profiles and supports the development of improved delivery strategies, including intravenous and nanoparticle-based formulations.
The everolimus toxicology data being presented by Sapu Nano aims to provide a more comprehensive understanding of how drug accumulation in specific tissues influences safety and efficacy. By moving beyond standard plasma concentration measurements, this approach could lead to more precise dosing regimens and reduced adverse effects. The findings are particularly relevant for oncology applications, where targeted delivery of therapeutics is critical to maximizing efficacy while minimizing systemic toxicity. Sapu Nano, a biotechnology company focused on nanomedicine platforms, intends to leverage these insights to enhance the therapeutic index of both established and novel drugs.
Oncotelic Therapeutics, through its wholly owned subsidiary Sapu Nano and other ventures, is actively developing treatments for rare pediatric cancers and other diseases. The company holds rare pediatric designations for Diffuse Intrinsic Pontine Glioma (DIPG) via OT-101 through its 45% joint venture GMP Bio, melanoma through CA4P, and Acute Myeloid Leukemia (AML) through OXi 4503. Additionally, Oncotelic acquired AL-101 for intranasal delivery of apomorphine, targeting Parkinson's disease, erectile dysfunction, and female sexual disorders. The company's AI-driven approach, bolstered by the acquisition of PointR Data Inc., aims to accelerate drug development and discovery.
The presentation at SOT 2026 is expected to attract attention from researchers and clinicians interested in nanomedicine and toxicology. By demonstrating the correlation between tissue drug levels and organ-specific outcomes, Sapu Nano's work could pave the way for more effective and safer drug delivery systems. This aligns with broader industry trends toward personalized medicine and precision dosing, where patient-specific factors are considered to optimize treatment outcomes. For more information about Oncotelic and its subsidiaries, visit the company's newsroom at https://ibn.fm/OTLC. The full press release detailing the presentation can be accessed at https://ibn.fm/kZzE3.
